Kiadis Pharma product portfolio
Kiadis Pharma has a number of novel products in clinical development..Its lead product ATIR™ addresses the shortage in availability of matched donors by enabling transplantations from partially matched (haploidentical) donors who are readily available within the patient’s family. ATIR™ is currently in Phase II of clinical development. Furthermore, with Rhitol™ and Reviroc™, Kiadis Pharma has two other cell-based product candidates in hemato-oncological indications in development (chronic Graft versus Host Disease and autologous transplantation respectively).
The current status of our products in clinical development: